Evelien Moorkens

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2021
Publications (10 Years): 8

Top Topics

Tyrosine Kinase

Rheumatoid Arthritis Patients

Health Insurance

Advanced Cancer

Top Venues

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Journal of market access & health policy

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Evelien Moorkens, Arnold G Vulto, Isabelle Huys
An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry? mAbs 12 (1) (2021)
Evelien Moorkens, Arnold G Vulto, James Kent, Lindsay McClure, Richard Boldero, Thibault Vanhove, Steven R A Simoens, Isabelle Huys
A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 35 (1) (2021)
Evelien Moorkens, Hannah Broux, Isabelle Huys, Arnold G Vulto, Steven R A Simoens
Economic evaluation of biosimilars for reimbursement purposes - what, when, how? Journal of market access & health policy 8 (1) (2020)
Evelien Moorkens, Teresa Barcina Lacosta, Arnold G Vulto, Martin Schulz, Gabriele Gradl, Salka Enners, Gisbert W Selke, Isabelle Huys, Steven R A Simoens
Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. Pharmaceuticals (Basel, Switzerland) 13 (10) (2020)
Evelien Moorkens, Arnold G Vulto, Isabelle Huys
Biosimilars in Belgium: a proposal for a more competitive market. Acta clinica Belgica 76 (6) (2020)
Evelien Moorkens, Steven Simoens, Per Troein, Paul Declerck, Arnold G Vulto, Isabelle Huys
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 33 (3) (2019)
Evelien Moorkens, Steven Simoens, Per Troein, Paul Declerck, Arnold G Vulto, Isabelle Huys
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 33 (3) (2019)
Evelien Moorkens, Arnold G Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber, Barbara Claus, Maria Dimitrova, Guenka Petrova, Ljiljana Sović-Brkičić, Juraj Slabý, Robin Šebesta, Ott Laius, Allan Karr, Morgane Beck, Jaana E Martikainen, Gisbert W Selke, Susan Spillane, Laura McCullagh, Gianluca Trifirò, Patricia Vella Bonanno, Asbjørn Mack, Antra Fogele, Anita Viksna, Magdalena Władysiuk, Helder Mota-Filipe, Dmitry Meshkov, Marija Kalaba, Simona Mencej Bedrač, Jurij Fürst, Corrine Zara, Peter Skiöld, Einar Magnússon, Steven Simoens
Policies for biosimilar uptake in Europe: An overview. PloS one 12 (12) (2017)